Animal disease model

Global Induced Pluripotent Stem Cells Market (2022 to 2027) - Growth, Trends, Covid-19 Impact and Forecasts - ResearchAndMarkets.com

Retrieved on: 
Wednesday, September 7, 2022
Science, Stem Cells, Other Science, Biotechnology, Research, Pharmaceutical, Health, FDA, Safety, Research, Potency (pharmacology), IPSC, Canadian International Council, Journal of Cell Science, Solution, Disease, Multiple sclerosis, Disulfiram-like drug, Cardiotoxicity, Drug discovery, Food, AgeX Therapeutics, Animal disease model, Drug development, Method, Journal, Cas9, Food and Drug Administration Amendments Act of 2007, Use, Therapy, Adult, B cell, Growth, International Journal of Molecular Sciences, Adoption, Pharmaceutical industry, Induce, Cell

The Drug Development Segment is Expected to Hold a Major Market Share in the Induced Pluripotent Stem Cells Market.

Key Points: 
  • The Drug Development Segment is Expected to Hold a Major Market Share in the Induced Pluripotent Stem Cells Market.
  • By application, the drug development segment holds the major segment in the induced pluripotent stem cell market.
  • Various research studies focusing on drug development studies with induced pluripotent stem cells have been on the rise in recent years.
  • Thus, the increasing necessity for induced pluripotent stem cells coupled with increasing investment in the health care department is known to propel the growth of the market in this region.

BenchSci Extends Impact on Drug Discovery With Addition of AI-Assisted Animal Model Selection

Retrieved on: 
Wednesday, July 28, 2021
Animal testing, Preclinical development, Animal disease model, Model organism, Experiment, Knowledge, Life sciences, Inquiry

BenchSci enables scientists to make more informed and precise animal model selections by providing evidence of successful utilization in experiments similar to their own.

Key Points: 
  • BenchSci enables scientists to make more informed and precise animal model selections by providing evidence of successful utilization in experiments similar to their own.
  • "We're proud to be introducing animal models to the BenchSci platform as we continue to focus on helping scientists accelerate preclinical research," says Casandra Mangroo, BenchSci's SVP of Product and Science.
  • Scientists will have the information they need to select the most appropriate animal model to advance their experiments."
  • BenchSci's animal model database includes:
    The addition of animal models to the platform is one more way that BenchSci is becoming a complete resource for all aspects of decision-making in experimental design.

InSphero and Pharmaceutical Companies Form Pre-Competitive Consortium to Advance Development of In Vitro Tools to Screen and Predict Drug-Induced Liver Injury (DILI)

Retrieved on: 
Wednesday, June 16, 2021
Biotechnology, General Health, Health, Stem cells, Pharmaceutical, Alternatives to animal testing, In vitro, In vivo, Animal disease model, Science, Biology, Natural sciences

The consortium will evaluate methods for recapitulating DILI-specific effects observed in animal models and patients using in vitro human and animal liver spheroid models and a DILI compound library.

Key Points: 
  • The consortium will evaluate methods for recapitulating DILI-specific effects observed in animal models and patients using in vitro human and animal liver spheroid models and a DILI compound library.
  • We intend to use 3D liver microtissues from animals and humans to evaluate DILI mechanisms leading to observed in vivo effects.
  • Each participating pharma member will provide a set of DILI compounds for 3D in vitro mechanistic investigations conducted by InSphero.
  • Through partnerships, InSphero supports pharmaceutical and biotechnology researchers in successful decision-making by accurately rebuilding the human physiology in vitro.

Taconic Biosciences Expands Scientific Advisory Board

Retrieved on: 
Monday, March 15, 2021
Taconic Biosciences, Taconic, Animal disease model

RENSSELAER, N.Y., March 15, 2021 (GLOBE NEWSWIRE) -- Taconic Biosciences, a global leader in providing drug discovery animal model solutions, announces Monica Gostissa, PhD, has joined its Scientific Advisory Board (SAB).

Key Points: 
  • RENSSELAER, N.Y., March 15, 2021 (GLOBE NEWSWIRE) -- Taconic Biosciences, a global leader in providing drug discovery animal model solutions, announces Monica Gostissa, PhD, has joined its Scientific Advisory Board (SAB).
  • The SAB collaborates with Taconic management, providing scientific insight and guidance to expand the companys product and service portfolio.
  • She will provide valuable expertise and direction as Taconic continues developing the best animal model solutions to inform human clinical outcomes," shared Nancy J. Sandy, Taconic Biosciences chief executive officer.
  • Taconic Biosciences is a fully-licensed, global leader in genetically engineered rodent models and services.

LabRoots Presents 10th Annual Laboratory Animal Sciences Online Virtual Event, to be held on February 10th

Retrieved on: 
Thursday, February 4, 2021
Applied ethics, Animal testing, Biology, Science and technology, Animal welfare, Bioethics, Laboratory techniques, Stem cells, Organoid, Labroots, Animal disease model

YORBA LINDA, Calif., Feb. 4, 2021 /PRNewswire-PRWeb/ -- LabRoots , the leading scientific social networking website, offering premier, interactive virtual events and webinars, today announced its Laboratory Animal Sciences virtual event scheduled on February 10, 2021.

Key Points: 
  • YORBA LINDA, Calif., Feb. 4, 2021 /PRNewswire-PRWeb/ -- LabRoots , the leading scientific social networking website, offering premier, interactive virtual events and webinars, today announced its Laboratory Animal Sciences virtual event scheduled on February 10, 2021.
  • MPS, emerging technologies such as spheroids, organoids and organs-on-chips) hold potential to increase translation and possibly serve as replacement or reduction for some animal models.
  • And, she will provide expanded definitions of the 3Rs that better address the complexity of appropriate animal use and welfare in contemporary society.
  • "By addressing animal research challenges via education, LabRoots is committed to bringing innovative advancements to the forefront of biomedical research," said Greg Cruikshank, Chief Executive Officer of LabRoots.

JW Therapeutics Presents Data from Pivotal Trial of Relma-cel at the 62nd ASH Annual Meeting

Retrieved on: 
Monday, December 7, 2020
Communication, Forward-looking statement, Animal disease model

No forward-looking statement can be guaranteed and actual results may differ materially from those we project.

Key Points: 
  • No forward-looking statement can be guaranteed and actual results may differ materially from those we project.
  • The complexity of the human body cannot be perfectly, or sometimes, even adequately modeled by computer or cell culture systems or animal models.
  • Also, we or others could identify safety, side effects or manufacturing problems with our products after they are on the market.
  • Shareholders and potential investors of JW Therapeutics are advised to exercise due care when dealing in the shares of JW Therapeutics.

Taconic Biosciences launches critical model for COVID-19 research

Retrieved on: 
Monday, October 26, 2020
Articles, Biology, Branches of biology, Taconic Biosciences, Taconic, Angiotensin-converting enzyme 2, Genetically modified mouse, Coronavirus disease, Transgene, Animal disease model, Genetic engineering

RENSSELAER, N.Y., Oct. 26, 2020 (GLOBE NEWSWIRE) -- Taconic Biosciences, a global leader in providing drug discovery animal model solutions, announces immediate humanized ACE2 mouse model availability for COVID-19 research.

Key Points: 
  • RENSSELAER, N.Y., Oct. 26, 2020 (GLOBE NEWSWIRE) -- Taconic Biosciences, a global leader in providing drug discovery animal model solutions, announces immediate humanized ACE2 mouse model availability for COVID-19 research.
  • Transgenic mice expressing the human ACE2 receptor overcome this challenge and thus are critical for COVID-19 research.
  • Taconic Biosciences is a fully-licensed, global leader in genetically engineered rodent models and services.
  • Founded in 1952, Taconic provides the best animal solutions so that customers can acquire, custom generate, breed, precondition, test, and distribute valuable research models worldwide.

INDIGO's Preclinical Animal Model Platform Expands Zebrafish Offering

Retrieved on: 
Tuesday, October 6, 2020
Biology, Branches of biology, Animal testing, Regenerative biomedicine, Organisms, Danio, Stem cell research, Zebrafish, Nuclear receptor, Animal disease model

STATE COLLEGE, Pa., Oct. 6, 2020 /PRNewswire-PRWeb/ --INDIGO Biosciences, the recognized industry leader in nuclear receptor research, has expanded their robust portfolio of in vitro animal model assays with three additional first-in-class zebrafish model systems.

Key Points: 
  • STATE COLLEGE, Pa., Oct. 6, 2020 /PRNewswire-PRWeb/ --INDIGO Biosciences, the recognized industry leader in nuclear receptor research, has expanded their robust portfolio of in vitro animal model assays with three additional first-in-class zebrafish model systems.
  • "This addition gives discovery scientists the ability to make key determinations on the correct animal model for their research with an ortholog that was not previously available before entering animal trials."
  • For researchers looking at nuclear receptor activity, zebrafish provide an attractive model as nearly all of the 48 human nuclear receptors are also present in the animal model.
  • With animal studies required by the FDA, selecting the animal model that provides the most representative human-surrogate is critical to assessing a potential drug's likelihood of unwanted effects.